Clinica Universidad de Navarra
Pamplona, Navarre, Spain
56 recruiting
Showing 1–20 of 78 trials
Recruiting
Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ovarian Cancer
Incyte Corporation466 enrolled157 locationsNCT07214779
Recruiting
Phase 1Phase 2
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
B Cell Precursor Acute Lymphoblastic Leukemia
Amgen281 enrolled109 locationsNCT04521231
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled157 locationsNCT07011732
Recruiting
Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
Daiichi Sankyo700 enrolled288 locationsNCT06578247
Recruiting
Phase 3
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
Adenovirus Infections
SymBio Pharmaceuticals180 enrolled61 locationsNCT07387367
Recruiting
Phase 2
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Diffuse Large B Cell Lymphoma
Miltenyi Biomedicine GmbH213 enrolled52 locationsNCT04844866
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled125 locationsNCT07213674
Recruiting
Phase 3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Multiple Myeloma
Pfizer1,116 enrolled89 locationsNCT05623020
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate CancerMetastatic Prostate Cancer
Genentech, Inc.210 enrolled25 locationsNCT05800665
Recruiting
Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
HR+/HER2-negative Breast Cancer
Totus Medicines241 enrolled18 locationsNCT05683418
Recruiting
Phase 3
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Eli Lilly and Company510 enrolled194 locationsNCT06338995
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Neoplasms
Hoffmann-La Roche405 enrolled21 locationsNCT06884618
Recruiting
Phase 1Phase 2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
Eli Lilly and Company58 enrolled45 locationsNCT06721013
Recruiting
Phase 1Phase 2
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Regeneron Pharmaceuticals387 enrolled40 locationsNCT03761108
Recruiting
Phase 3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Small Cell Lung CancerLimited Stage Small Cell Lung Cancer
Amgen400 enrolled204 locationsNCT06117774
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Alzheimer s Disease
Bristol-Myers Squibb586 enrolled106 locationsNCT06976216
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled65 locationsNCT06090539
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled138 locationsNCT06615479
Recruiting
Phase 1Phase 2
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Solid Tumor, Adult
BioInvent International AB197 enrolled25 locationsNCT04219254